Trial Profile
A prospective study assessing association between Ustekinumab trough levels and antibodies and response and remission to induction and maintainence Ustekinumab treatment in Crohn's Disease patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2019
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics; Therapeutic Use
- 10 Oct 2019 Results (n=49) published in the Digestive Diseases and Sciences.
- 15 Dec 2016 New trial record
- 19 Oct 2016 Results presented at the 24th United European Gastroenterology Week